JAK2 in Myeloproliferative Neoplasms: Still a Protagonist

The discovery of the activating V617F mutation in Janus kinase 2 (JAK2) has been decisive for the understanding of myeloproliferative neoplasms (MPN). Activated JAK2 signaling by JAK2, CALR, and MPL mutations has become a focus for the development of targeted therapies for patients with MPN. JAK2 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bader, Michael Stephan, Meyer, Sara Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874480/
https://www.ncbi.nlm.nih.gov/pubmed/35215273
http://dx.doi.org/10.3390/ph15020160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874480/
https://www.ncbi.nlm.nih.gov/pubmed/35215273
http://dx.doi.org/10.3390/ph15020160

Ejemplares similares